Testosterone: medium ester

Testosterone Isocaproate

Testosterone isocaproate is a testosterone ester that makes up 60 mg of each 1 mL of Sustanon 250 on its label, alongside 30, 60 and 100 mg of three other esters.1

Moderate evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Testosterone Isocaproate after one dose: 50% at ~4 days, 25% at 8 days, 12.5% at 12 days.

Drawn from the half-life in the app's model, ~4 days. The model's figures

Testosterone isocaproate is one of four esters of testosterone in Sustanon 250.1,2 The UK label gives the indication as testosterone replacement therapy for male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.1

The app lists testosterone isocaproate with a half-life of about 4 days (96 hours), an intramuscular route and a typical dose of 100 to 200 mg a week. The figures row at the top of the page and the evidence grade beside it are the app's own. None of the sources cited below states a half-life, a bioavailability or a weekly dose for isocaproate on its own, and the labels give pharmacokinetic figures only for the four-ester mixture.1,2 A search of PubMed on 16 November 2026 for the phrase testosterone isocaproate in titles and summaries, one phrase in one database, returned 12 records, and none of the 12 titles describes a study of the ester given alone.

In people

The UK label states that the esters in Sustanon 250 are hydrolysed into the natural hormone testosterone as soon as they enter the general circulation, and the New Zealand data sheet gives the same statement.1,2 The UK label states that testosterone is metabolised to dihydrotestosterone and estradiol and is excreted mainly in urine as conjugates of etiocholanolone and androsterone.1

In hypogonadal men, the UK label states that treatment with Sustanon 250 results in a clinically significant rise of plasma testosterone, dihydrotestosterone, estradiol and androstenedione and a decrease of sex hormone binding globulin, and that luteinizing hormone (LH) and follicle-stimulating hormone (FSH) are restored to the normal range.1

In vitro and in blood samples

The UK label states that testosterone shows over 97% non-specific binding to plasma proteins and sex hormone binding globulin in in vitro tests.1 Solheim and colleagues, writing in Drug Testing and Analysis in 2022, state that direct detection of intact testosterone esters in doping control samples is "hampered by the rapid hydrolysis by esterases present in the blood".3

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~4 days
Bioavailability
95%
Typical dose
100–200 mg/week
Route
IM
Time to peak
~48 h

The app's figures for testosterone isocaproate are a half-life of about 4 days (96 hours), a time to peak of about 48 hours, a bioavailability of 95% and a duration of 192 hours, by intramuscular injection. None of the sources cited states any of these four figures for isocaproate on its own. For a single dose of the four-ester mixture, the UK label states that total plasma testosterone reaches peak levels of approximately 70 nmol/l (Cmax), approximately 24 to 48 hours (tmax) after administration, and returns to the lower limit of the normal range in males in approximately 21 days; the New Zealand data sheet gives the same figures.1,2 The app's time to peak of 48 hours sits at the upper end of the label's 24 to 48 hours, which describes total testosterone after the mixture, not the ester.

Katz and colleagues, Journal of Clinical Pathology, 1993, evaluated hormone replacement in 21 male and 11 female patients with beta thalassaemia major and various forms of hypogonadism, using intramuscular testosterone of propionate 15 mg, phenylpropionate 30 mg, isocaproate 30 mg and decanoate 50 mg, half the strengths in the UK label.4,1 The record reports that intramuscular testosterone produced peak values seven days after injection, in a passage that begins with male patients, without stating the analyte measured or the sampling times.4 The authors' conclusions name smaller intramuscular doses of 10 to 25 mg every one to two weeks, and lower than recommended doses where growth is incomplete.4

Table 3.1Half-life and pharmacokinetics6 rows
ParameterValueNote
Half-life~4 days (96 hours)The app's figure; none of the sources cited states a half-life for isocaproate on its own.
Time to peak~48 hoursThe app's figure for the ester. For the mixture, the UK label gives approximately 24 to 48 hours for total plasma testosterone after a single dose.1
Bioavailability (IM)95%The app's figure; none of the sources cited states one.
Duration of activity192 hours (8 days)The app's figure; none of the sources cited states one.
Peak total testosterone, mixtureApproximately 70 nmol/lSingle dose of Sustanon 250, UK label and New Zealand data sheet.1,2 Main and colleagues report mean total testosterone of 58 ± 19 nmol/L one day after 250 mg Sustanon in 9 men.7
Return to lower limit of normal, mixtureApproximately 21 daysPlasma testosterone in males after a single dose of Sustanon 250, UK label.1

In the chart below, the curve models isocaproate alone from the app's half-life of 96 hours and time to peak of 48 hours, neither of which any cited source states for the ester. The 100 mg starting dose and the 20 to 400 mg range are also not drawn from a cited source, and the curve models the ester, not total testosterone. The intervals listed are those the cited sources used for mixtures: every 14 days in the 2019 trial of Gharahdaghi and colleagues and every 21 days in the UK label.5,1

Level over 6 weeks

Interval between doses

Level, as a share of the peak after one 100 mg dose

As studied: every 14 days5, every 21 days1.

An illustration from a pharmacokinetic model using a half-life of 96 hours (4 days). It is not a measured level or a suggested dose.

4

What Sustanon 250 contains per mL

The four esters in each 1 mL ampoule add up to 250 mg, the strength in the product name, and the label gives 176 mg of testosterone per mL.1 The converter below multiplies a volume by the label's 60 mg per mL of isocaproate; it is arithmetic on the label strength of this product only.1

Table 4.1What Sustanon 250 contains per mL4 rows
EsterAmount per 1 mLSource
Testosterone propionate30 mgUK label1 and New Zealand data sheet2
Testosterone phenylpropionate60 mgUK label1 and New Zealand data sheet2
Testosterone isocaproate60 mgUK label1 and New Zealand data sheet2
Testosterone decanoate100 mgUK label1 and New Zealand data sheet2

Strength converter

Isocaproate in Sustanon 250 (label strength): 60 mg per mL1

Arithmetic only: the amount is the volume times the strength. The vial's own label states its strength.

5

Human studies

Each human study below included a group given isocaproate within an ester mixture, so none reports a result for the ester on its own; the Forsdahl study also had a group given testosterone undecanoate alone, and the mixture in the Büyükgebiz study had three esters.

Table 5.1Human studies5 rows
Study and yearDesignPeopleDose and lengthMain result
Büyükgebiz, Hormone Research, 19956Treatment series; no comparison group described in the PubMed record13 boys with constitutional delayed puberty, mean age 14.9 +/- 0.6 years200 mg testosterone intramuscularly, 4 times at 3-week intervals, as propionate, phenylpropionate and isocaproate; 2 years of follow-upAll 13 entered puberty after the last dose; growth rate rose from 4.5 +/- 0.5 to 8.4 +/- 1.6 cm/year (before and after treatment, no comparison group described); height for bone age SD score did not change significantly
Gharahdaghi and colleagues, J Cachexia Sarcopenia Muscle, 20195Randomised, double-blinded, saline placebo, with resistance training; registered NCT0215283918 non-hypogonadal healthy men aged 65 to 75 years; 9 per groupSustanon 250 mg "biweekly" over 6 weeksTotal fat-free mass gain larger on testosterone (P=0.007), total fat mass lower (P=0.02); no adverse events reported
Main and colleagues, Andrology, 20277Randomised, double-blinded, placebo-controlled; small RNA outcomes19 healthy eugonadal men aged 20 to 30 years250 mg mixed testosterone esters as Sustanon 250 or placebo, day 0 and day 2119 Sustanon-responsive small RNAs at day 1; 160 altered at day 42, when testosterone had returned to baseline (n = 19 at day 1, n = 12 at day 42)
Solheim and colleagues, Drug Testing and Analysis, 20223Dried blood spot sampling for ester detection, placebo group9 men given Sustanon 250, 10 given placeboTwo intramuscular injections of Sustanon 250; interval not stated in the PubMed recordMethod suitable for direct detection of four esters including isocaproate; Sustanon detected in all subjects for at least 5 days, with a detection window up to 14 days for three of the esters, which the record does not name
Forsdahl and colleagues, Drug Testing and Analysis, 20158Clinical study of ester detection windows in blood6 participantsOne injection of 1000 mg testosterone undecanoate or of the four-ester mixture; blood for 60 daysAll investigated esters detected; detection time depended on the ester

Deeper analysis: Büyükgebiz, constitutional delayed puberty

Büyükgebiz, of the Department of Pediatric Endocrinology at Dokuz Eylül Medical Faculty in Izmir, Turkey, reported in Hormone Research in 1995 on 13 boys with constitutional delayed puberty treated with testosterone propionate, testosterone phenylpropionate and testosterone isocaproate.6 Each received 200 mg testosterone intramuscularly, 4 times at 3-week intervals, and was followed for 2 years.6 All 13 entered puberty after the last dose (testicular volume of 4 ml or more), while height for bone age SD score went from a mean of -1.1 to -1.3, a change that was not significant.6 The PubMed record does not describe a comparison group, name a product, report adverse events or state funding or ties to a sponsor, so the rise in growth rate is a before and after change in 13 boys.6 The UK label for Sustanon 250 states that safety and efficacy have not been adequately determined in children and adolescents, that high dosages may accelerate epiphyseal closure and sexual maturation, and that precocious sexual development, more frequent erections, phallic enlargement and premature epiphyseal closure have been reported in prepubertal children using androgens.1 The author concluded that "A combination of testosterone esters in a given dose and schedule is a safe and effective treatment for prepubertal boys with CDP."6

Deeper analysis: Solheim and colleagues, ester detection

Solheim and colleagues, with affiliations including the University of Copenhagen, Anti-Doping Denmark and Oslo University Hospital, tested a method for detecting intact testosterone esters in dried blood spots, where drying inactivates the hydrolase enzymes that otherwise degrade them.3 The PubMed record does not name which three esters had a detection window of up to 14 days, so no figure for isocaproate can be taken from it, and it does not state funding or the authors' own limitations.3 It reports 9 men given Sustanon 250 and 10 given placebo, the group sizes of the Main trial, whose paper cites methods published by Solheim and colleagues; the records do not state whether the two papers describe the same men.3,7

Deeper analysis: Gharahdaghi and colleagues, older men with resistance training

Gharahdaghi and colleagues, of the University of Nottingham, gave 18 non-hypogonadal healthy men aged 65 to 75 years either saline placebo (n = 9) or Sustanon 250 mg (n = 9) biweekly over 6 weeks of whole-body resistance training.5 Testosterone augmented total fat-free mass (P=0.007), legs fat-free mass (P=0.02) and appendicular fat-free mass (P=0.001) gains and decreased total fat mass (P=0.02), muscle protein synthesis rate was 2.13 ± 0.21% a day on testosterone against 1.34 ± 0.13% a day on placebo (P=0.0009), and absolute breakdown rates were also higher on testosterone, 140.2 ± 15.8 against 90.2 ± 11.7 g a day (P=0.02).5 The paper states that no adverse events were reported, that the Medical Research Council and the National Institute for Health Research supported the work, and that no conflict of interest was declared.5 The authors conclude that "T coupled with RET is an effective short-term intervention to improve muscle mass/function in older non-hypogonadal men", and write that older men receiving testosterone therapy need careful monitoring because of its potential risks.5

Deeper analysis: Main and colleagues, small RNAs

Main and colleagues, of the Department of Growth and Reproduction at Rigshospitalet in Copenhagen, analysed circulating small noncoding RNAs in 19 healthy eugonadal men aged 20 to 30 years given Sustanon 250 or placebo on day 0 and day 21.7 Of 51 serum samples analysed, 28 came from the placebo group and 23 from the Sustanon group, which contributed 5 on day 42.7 The authors name the small sample size (n = 19) and the fall to n = 12 on day 42 as limits, and write that the results "need cautious interpretation and further validation".7 Funding came from the Novo Nordisk Foundation, the Svend Andersen Foundation and the Independent Research Fund Denmark; the Sustanon trial was supported by the Partnership for Clean Competition, the Innovation Fund Denmark's Industrial PhD program and Anti-Doping Denmark; the authors declare no conflicts of interest.7 They write that several responsive RNAs, notably miR-214-3p and snoRNA U3, show potential as biomarkers of androgen misuse.7

6

Doses reported in studies and on labels

The app's typical dose for isocaproate is 100 to 200 mg a week, and no cited source reports a dose of isocaproate alone. For comparison with the app's weekly figure, the UK label's one injection of 1 ml per 3 weeks contains 60 mg of isocaproate, which averages about 20 mg a week.1

Table 6.1Doses reported in studies and on labels5 rows
SourceDoseFrequencyLength
UK label, adults11 ml of Sustanon 250 (60 mg isocaproate among 250 mg of esters)One injection per 3 weeks is usually adequateNot stated
UK label, female-to-male transsexuals11 ml of Sustanon 250From every two weeks to every four weeks, as used by different specialist centresNot stated
New Zealand data sheet, adults21 ml of Sustanon 250One injection per three weeks is usually adequateNot stated
Büyükgebiz, 1995, 13 boys6200 mg testosterone intramuscularly, as three esters including isocaproate4 doses at 3-week intervals2 years of follow-up
Gharahdaghi and colleagues, 2019, 9 men5Sustanon 250 mgBiweekly6 weeks

The UK label adds that in general the dose is adjusted to the response of the individual patient, and the New Zealand data sheet states the same.1,2

7

Side effects reported

None of the sources cited reports side effects of isocaproate on its own. The UK label for Sustanon 250 lists adverse reactions "associated with androgen therapy in general", each as common (1 in 100 to under 1 in 10) or not known, with pulmonary oil microembolism listed as rare.1 The reactions listed include polycythaemia, fluid retention, weight increased, hypertension, acne, gynaecomastia, oligospermia, priapism, increased PSA and increased haematocrit.1 The table also lists progression of a sub-clinical prostatic cancer, depression, nervousness, altered mood, libido changes, nausea, abnormal hepatic function, pruritus, myalgia, ejaculation disorder, benign prostatic hyperplasia, abnormal lipids, and increased red blood cell count and haemoglobin, and the label states that injectables in general may cause a local reaction at the injection site.1 The label also states that, due to the nature of Sustanon 250, side effects cannot be quickly reversed by discontinuing medication.1

The label lists as contraindications pregnancy, known or suspected carcinoma of the prostate or breast, breast-feeding and hypersensitivity to an ingredient, including arachis oil, and states that Sustanon 250 is therefore contraindicated in patients allergic to peanuts or soya.1 It states that pulmonary microembolism of oily solutions can in rare cases lead to cough, dyspnoea, malaise, hyperhydrosis, chest pain, dizziness, paraesthesia or syncope, that these reactions may occur during or immediately after the injection and are reversible, and that the patient is to be observed during and immediately after each injection.1 Its warnings also describe thrombotic events (deep-vein thrombosis, pulmonary embolism, ocular thrombosis) reported in patients with thrombophilia or risk factors for venous thromboembolism, and a deepening of the voice that may be irreversible.1 The label states that testosterone has been subject to abuse, typically at doses higher than recommended for the approved indication and in combination with other anabolic androgenic steroids, and that abuse of testosterone and other anabolic androgenic steroids can lead to serious adverse reactions including cardiovascular events, with fatal outcomes in some cases, and hepatic and psychiatric events, and may result in dependence and withdrawal symptoms.1 In the 2019 trial of Gharahdaghi and colleagues, 9 men received Sustanon 250 mg biweekly for 6 weeks and the paper states that no adverse events were reported.5

8

Bloodwork and markers

The app lists total testosterone, free testosterone, estradiol (E2), hematocrit, lipids and PSA as markers for isocaproate, and flags it as aromatizing and suppressive. The UK label for Sustanon 250 asks physicians to consider monitoring digital rectal examination of the prostate, PSA, haematocrit and haemoglobin before the start of treatment, at quarterly intervals for the first 12 months and yearly thereafter, and in long-term androgen therapy also liver function tests and lipid profile; it states that testosterone level is to be monitored at baseline and at regular intervals.1 The label states that treatment of hypogonadal men decreases serum LDL-C, HDL-C and triglycerides and increases haemoglobin and haematocrit, which may lead to polycythaemia, and that no clinically relevant changes in liver enzymes and PSA have been reported.1

In 6 healthy young men treated with Sustanon, Albrethsen and colleagues, Journal of Clinical Endocrinology and Metabolism, 2023, reported that circulating insulin-like factor 3, testosterone and LH decreased during the experimental testicular suppression and returned to baseline after the suppression was released; the PubMed record does not state the regimen or which testosterone was measured, and it carries an erratum (J Clin Endocrinol Metab 2024;109(4):e1371).9 None of the sources cited states the aromatizing or suppressive flag for isocaproate itself; the UK label states that testosterone is metabolised to dihydrotestosterone and estradiol.1

Table 9.1Regulatory and anti-doping status4 rows
BodyStatementNote
UK (emc, Sustanon 250)1Prescription only medicine; date of first authorisation 28 February 1973The label states that Sustanon 250 can interfere with anti-doping testing.
New Zealand (Medsafe)2Prescription medicine; date of first approval 31 December 1969Data sheet revised 14 January 2026.
United States, 21 CFR 1308.13(f)10Schedule III anabolic steroids: the list names testosterone and covers listed substances "including its salts, esters and ethers", unless specifically excepted or unless listed in another scheduleThe text does not name isocaproate; 21 CFR 1300.01 defines an anabolic steroid as a drug or hormonal substance chemically and pharmacologically related to testosterone.11
WADA Prohibited List 202612Section S1.1, anabolic androgenic steroids, prohibited at all times (in and out of competition), when administered exogenously, names testosterone and extends to similar substances "including their esters"Isocaproate is not named in the list text.
10

Storage and handling

The UK label for Sustanon 250 states a shelf life of 5 years and the storage conditions of below 30°C, no refrigeration or freezing, and storage in the original package to protect from light.1

11

What is not known

None of the sources cited states a half-life, time to peak, bioavailability or duration for testosterone isocaproate on its own, so the app's figures are not matched by a cited figure. The label's time to peak of 24 to 48 hours and the seven days reported by Katz and colleagues differ, and the two come from different populations, doses and designs, which the sources cited do not reconcile.1,4 A search of PubMed on 16 November 2026 for the phrase testosterone isocaproate in titles and summaries, one phrase in one database, returned 12 records, and none of the 12 titles describes a study of the ester given alone.

What is testosterone isocaproate?

Testosterone isocaproate is one of four esters of testosterone in Sustanon 250, at 60 mg in each 1 mL ampoule according to its label.1

What is the half-life of testosterone isocaproate?

The app lists a half-life of about 4 days (96 hours) for testosterone isocaproate, and none of the sources cited states a half-life for the ester. For a single dose of the four-ester mixture, the UK label states that plasma testosterone returns to the lower limit of the normal range in males in approximately 21 days.1

How long can testosterone isocaproate be detected in blood?

None of the sources cited gives a duration for the ester alone, and the app lists a duration of 192 hours (8 days). In 9 men given two intramuscular injections of Sustanon 250, Solheim and colleagues reported that Sustanon was detected in dried blood spots in all subjects for at least 5 days, with a detection window up to 14 days for three of the four esters, which is the window of one dried blood spot method.3 Forsdahl and colleagues reported that the detection time in blood depended on the ester administered.8

How long until testosterone isocaproate peaks?

The app lists a time to peak of about 48 hours for testosterone isocaproate, and none of the sources cited states a time to peak for the ester. The UK label states that total plasma testosterone peaks approximately 24 to 48 hours after a single dose of Sustanon 250, while Katz and colleagues reported peak values seven days after injection of a four-ester mixture at half the label's strengths in patients with beta thalassaemia major.1,4

How much testosterone isocaproate is in Sustanon 250?

Each 1 mL of Sustanon 250 contains 60 mg of testosterone isocaproate, according to the UK label and the New Zealand data sheet.1,2

Is testosterone isocaproate banned in sport?

The WADA Prohibited List 2026 names testosterone among the anabolic androgenic steroids prohibited at all times, in and out of competition, when administered exogenously, and extends the class to similar substances "including their esters".12 The list text does not name isocaproate but extends the class to esters, and the UK label for Sustanon 250 states that the product can interfere with anti-doping testing.12,1

Is testosterone isocaproate a controlled substance?

In the United States, 21 CFR 1308.13(f) places anabolic steroids in Schedule III, names testosterone, and covers the listed substances including their salts, esters and ethers, unless specifically excepted or unless listed in another schedule.10 The regulation text does not name isocaproate.

What are the side effects of testosterone isocaproate?

None of the sources cited reports side effects of isocaproate on its own. The UK label for Sustanon 250 lists reactions associated with androgen therapy in general, including polycythaemia, fluid retention, hypertension, acne, gynaecomastia, oligospermia, priapism, increased PSA and increased haematocrit, and lists pulmonary oil microembolism as rare.1 The table also lists further reactions, including progression of a sub-clinical prostatic cancer, depression and abnormal hepatic function.1

Has testosterone isocaproate been studied on its own?

The sources cited include no study of the ester given alone, and the human studies cited gave isocaproate as one ester in a mixture, such as the 13 boys in Büyükgebiz's 1995 study of delayed puberty and the 9 men in Solheim and colleagues' 2022 detection study.6,3 A search of PubMed on 16 November 2026 for the phrase testosterone isocaproate in titles and summaries, one phrase in one database, returned 12 records, and none of the 12 titles describes a study of the ester given alone.

14

References

  1. Aspen Pharma Trading Limited. Sustanon 250, 250mg/ml solution for injection. Summary of Product Characteristics, electronic medicines compendium (UK), text revised December 2025. emc SmPC
  2. Pharmacy Retailing (NZ) Ltd (Healthcare Logistics). Sustanon 250 New Zealand Data Sheet. Medsafe, text revised 14 January 2026. Medsafe data sheet
  3. Solheim SA, Levernaes MCS, Mørkeberg J, et al. Stability and detectability of testosterone esters in dried blood spots after intramuscular injections. Drug Test Anal 2022. PMID 33733610
  4. Katz M, De Sanctis V, Vullo C, et al. Pharmacokinetics of sex steroids in patients with beta thalassaemia major. J Clin Pathol 1993. PMID 8157756
  5. Gharahdaghi N, Rudrappa S, Brook MS, et al. Testosterone therapy induces molecular programming augmenting physiological adaptations to resistance exercise in older men. J Cachexia Sarcopenia Muscle 2019. PMC6903447
  6. Büyükgebiz A. Treatment of constitutional delayed puberty with a combination of testosterone esters. Horm Res 1995. PMID 8719438
  7. Main AM, Solheim SA, Wagner SP, et al. Temporal Effects of Exogenous Testosterone on the Circulating Small Noncoding RNA Landscape in a Placebo-Controlled Human Study. Andrology 2027;15(1):e70429. PMC13748923
  8. Forsdahl G, Erceg D, Geisendorfer T, et al. Detection of testosterone esters in blood. Drug Test Anal 2015. PMID 26695486
  9. Albrethsen J, Østergren PB, Norup PB, et al. Serum Insulin-like Factor 3, Testosterone, and LH in Experimental and Therapeutic Testicular Suppression. J Clin Endocrinol Metab 2023. PMID 37235781
  10. US Drug Enforcement Administration. 21 CFR 1308.13, Schedule III. Electronic Code of Federal Regulations (version of 1 November 2026). 21 CFR 1308.13
  11. US Drug Enforcement Administration. 21 CFR 1300.01, Definitions. Electronic Code of Federal Regulations (version of 1 November 2026). 21 CFR 1300.01
  12. World Anti-Doping Agency. Prohibited List 2026 (International Standard). In force 1 January 2026. WADA list 2026